Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05205291 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 7, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Aug 31, 2025 to Aug 31, 2026v5 Show 4 more changesShow less
    • Enrollment target: 24 to 30
    • Eligibility criteria expanded, about 749 words
    • Site contact updated
    • Study arms: 2 to 3
  2. Site contact updatedv4
  3. Primary completion date: Aug 31, 2024 to Aug 31, 2025
    • Study completion date: Sep 30, 2024 to Aug 31, 2025
    • Study description expanded, about 614 words
    • Site contact updated
    v3
  4. Start date changed from estimate of Feb 1, 2022 to Feb 28, 2022v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
It is not known what causes Parkinson's disease and what makes it worsen over time. Research conducted in the past few years has highlighted the possible role of inflammation on this process but its actual mechanisms are still obscure. In this study, the investigators aim to gain understanding on how inflammation is increased in Parkinson's disease and what are its mechanisms, by performing two Positron Emission Tomography (PET) scans using the tracer \[11C\]PBR28, that takes pictures of the brain highlighting the areas of inflammation, before and after the administration of a compound called Lipopolysaccharide or LPS, that is known to cause a mild degree of inflammation. The investigators will couple this study with two venous blood draws to measure the levels of circulating molecules of inflammation.
Trial Details
NCT Number NCT05205291
Lead Sponsor University of Exeter
Conditions
(from sponsor)		 Neurodegenerative Diseases, Parkinson Disease, REM Sleep Behavior Disorder (iRBD)
Related terms Inflammation, Neurodegenerative Diseases, Parkinson Disease, REM Sleep Behavior Disorder
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov